Table 3.
Levels of prelymphodepletion cGFAP/cNfL and day 1 sNfL do not correlate with risk of subsequent ICANS
| PLAT-02, cohort 1 |
PLAT-02, cohort 2 |
PLAT-05 |
All patients |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Median (pg/mL) | P value | N | Median (pg/mL) | P value | N | Median (pg/mL) | P value | N | Median (pg/mL) | P value | N | |
| cGFAP prelymphodepletion | ||||||||||||
| No ICANS | 5798 | 24 | 2210 | 36 | 1838 | 14 | 3027 | 74 | ||||
| ICANS | 5012 | .9479 | 17 | 1661 | .3240 | 37 | 899.6 | .4485 | 9 | 2738 | .9305 | 63 |
| cNfL prelymphodepletion | ||||||||||||
| No ICANS | 294.5 | 24 | 860.7 | 36 | 674.5 | 14 | 632.2 | 74 | ||||
| ICANS | 532.4 | .1749 | 17 | 670.6 | .7358 | 37 | 96.65 | .0982 | 9 | 538.2 | .7460 | 63 |
| sNfL | ||||||||||||
| Day 1 | ||||||||||||
| No ICANS | 380.2 | 24 | 122.2 | 36 | 288.3 | 13 | 215.5 | 73 | ||||
| ICANS | 356.5 | >.9999 | 19 | 164.3 | .5964 | 38 | 131.3 | .8811 | 9 | 203.0 | .7709 | 66 |
The ICANS group comprises all patients with any grade of neurotoxicity. Mann-Whitney test was used for comparing the ICANS and no ICANS groups within each cohort and for each biomarker, no adjustment was made for multiple comparisons.